stockrowFractyl Health, Inc.
GUTS Healthcare Biotechnology
Fractyl Health, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $93,000.00, down 22.5% from fiscal 2023.
- Revenue
- −57.1%
- EPS
- +71.9%
- Free cash flow
- +25.3%
- Total debt
- +1.54%
Quarter to June 2026, against a year earlier
Follow GUTS
Alert me
Fractyl Health, Inc. (GUTS) Altman Z-score
Fractyl Health, Inc.'s Altman Z-score for fiscal 2024 is −6.98, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2024 | −6.98 | — |
How fiscal 2024’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.48 | — | 0.58 | |
| Retained earnings / total assets | (3.84) | — | −5.38 | |
| EBIT / total assets | (0.87) | — | −2.86 | |
| Market value of equity / total liabilities | 1.13 | — | 0.68 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | −6.98 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −14.81 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | −6.7× |
| GUTS Fractyl Health, Inc. | −7.0× |
| DARE Dare Bioscience, Inc. compare | −8.9× |
| BOLT Bolt Biotherapeutics, Inc. compare | −12.7× |
| HIND Vyome Holdings, Inc. compare | −22.0× |
| CASIF CASI Pharmaceuticals Inc. compare | −47.1× |
| AEON AEON Biopharma, Inc. compare | — |
| NCEL NewcelX Ltd. compare | — |
| PBM Psyence Biomedical Ltd. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets